VANDA PHARMACEUTICALS INC. Deferred Income Tax Assets, Net
VANDA PHARMACEUTICALS INC. (VNDA) had Deferred Income Tax Assets, Net of $0 as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-02-12
- 2025-12-31: Deferred Income Tax Assets, Net $0.00.
- 2025-09-30: Deferred Income Tax Assets, Net $103.07M.
- 2025-06-30: Deferred Income Tax Assets, Net $97.14M.
- 2025-03-31: Deferred Income Tax Assets, Net $89.15M.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-12 |
| 2025-09-30 | $103.07M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $97.14M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $89.15M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $81.44M 10-K · filed 2026-02-12 |
| 2024-09-30 | $79.36M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $76.56M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $75.34M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $75.00M 10-K · filed 2025-02-14 |
| 2023-09-30 | $67.77M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $70.48M 10-Q · filed 2023-07-28 |
| 2023-03-31 | $71.75M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $74.04M 10-K · filed 2024-02-08 |
| 2022-09-30 | $74.53M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $72.69M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $70.80M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $74.88M 10-K · filed 2023-02-09 |
| 2021-09-30 | $76.11M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $78.64M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $80.36M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $81.52M 10-K · filed 2022-02-24 |
| 2020-09-30 | $83.86M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $85.56M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $86.64M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $87.68M 10-K · filed 2021-02-11 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |